David Nierengarten
Stock Analyst at Wedbush
(4.43)
# 322
Out of 5,182 analysts
233
Total ratings
55.44%
Success rate
17.59%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.55 | +141.76% | 7 | Apr 20, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $53 → $58 | $42.46 | +36.60% | 7 | Apr 16, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $12.67 | +42.07% | 10 | Apr 16, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $5.12 | +114.84% | 15 | Apr 16, 2026 | |
| FENC Fennec Pharmaceuticals | Reiterates: Outperform | $13 | $6.73 | +93.16% | 4 | Apr 16, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $80 | $73.39 | +9.01% | 2 | Apr 14, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.73 | +105.03% | 5 | Apr 13, 2026 | |
| NUVL Nuvalent | Reiterates: Outperform | $125 | $108.24 | +15.48% | 7 | Apr 8, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $20 → $17 | $10.89 | +56.11% | 11 | Apr 1, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $56 → $58 | $47.80 | +21.34% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $23.47 | +27.82% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $37.00 | +48.65% | 5 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $834.45 | +19.84% | 25 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $8 | $7.88 | +1.52% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.43 | +249.65% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $95 | $90.92 | +4.49% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $65 | $31.19 | +108.40% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $114.98 | -4.33% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $71.41 | +23.23% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $24.25 | +27.84% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $9.26 | +169.98% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $15.21 | -53.98% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.39 | +403.60% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.80 | +103.13% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $15.71 | -49.08% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $34.58 | -42.16% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $50.95 | -21.49% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $68.87 | -41.92% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $13.39 | +34.43% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.89 | +208.48% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.58 | +31,545.57% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.94 | +571.14% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $25.06 | +199.28% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.60 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.23 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.79 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.55
Upside: +141.76%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53 → $58
Current: $42.46
Upside: +36.60%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.67
Upside: +42.07%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.12
Upside: +114.84%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.73
Upside: +93.16%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $80
Current: $73.39
Upside: +9.01%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.73
Upside: +105.03%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $108.24
Upside: +15.48%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $17
Current: $10.89
Upside: +56.11%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $47.80
Upside: +21.34%
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $23.47
Upside: +27.82%
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.00
Upside: +48.65%
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $834.45
Upside: +19.84%
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $7.88
Upside: +1.52%
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.43
Upside: +249.65%
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $90.92
Upside: +4.49%
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $31.19
Upside: +108.40%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $114.98
Upside: -4.33%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $71.41
Upside: +23.23%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $24.25
Upside: +27.84%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $9.26
Upside: +169.98%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $15.21
Upside: -53.98%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.39
Upside: +403.60%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.80
Upside: +103.13%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $15.71
Upside: -49.08%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $34.58
Upside: -42.16%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $50.95
Upside: -21.49%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $68.87
Upside: -41.92%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $13.39
Upside: +34.43%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.89
Upside: +208.48%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.58
Upside: +31,545.57%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.94
Upside: +571.14%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $25.06
Upside: +199.28%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.23
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.79
Upside: -